Genmab could benefit from potential new FDA endpoint, say analysts
According to Jyske Bank and Artha Kapitalforvaltning, the clear statement from the FDA expert panel in favor of a new endpoint is good news for Genmab.
by MARKETWIRE
Genmab could benefit from potential new rules for the approval of new drugs for bone marrow cancer in the US, several analysts say.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
